218 related articles for article (PubMed ID: 22546852)
1. 14-3-3 regulates the LNK/JAK2 pathway in mouse hematopoietic stem and progenitor cells.
Jiang J; Balcerek J; Rozenova K; Cheng Y; Bersenev A; Wu C; Song Y; Tong W
J Clin Invest; 2012 Jun; 122(6):2079-91. PubMed ID: 22546852
[TBL] [Abstract][Full Text] [Related]
2. Expression level and differential JAK2-V617F-binding of the adaptor protein Lnk regulates JAK2-mediated signals in myeloproliferative neoplasms.
Baran-Marszak F; Magdoud H; Desterke C; Alvarado A; Roger C; Harel S; Mazoyer E; Cassinat B; Chevret S; Tonetti C; Giraudier S; Fenaux P; Cymbalista F; Varin-Blank N; Le Bousse-Kerdilès MC; Kiladjian JJ; Velazquez L
Blood; 2010 Dec; 116(26):5961-71. PubMed ID: 20870899
[TBL] [Abstract][Full Text] [Related]
3. Lnk constrains myeloproliferative diseases in mice.
Bersenev A; Wu C; Balcerek J; Jing J; Kundu M; Blobel GA; Chikwava KR; Tong W
J Clin Invest; 2010 Jun; 120(6):2058-69. PubMed ID: 20458146
[TBL] [Abstract][Full Text] [Related]
4. Lnk controls mouse hematopoietic stem cell self-renewal and quiescence through direct interactions with JAK2.
Bersenev A; Wu C; Balcerek J; Tong W
J Clin Invest; 2008 Aug; 118(8):2832-44. PubMed ID: 18618018
[TBL] [Abstract][Full Text] [Related]
5. SH2B3 (LNK) mutations from myeloproliferative neoplasms patients have mild loss of function against wild type JAK2 and JAK2 V617F.
Koren-Michowitz M; Gery S; Tabayashi T; Lin D; Alvarez R; Nagler A; Koeffler HP
Br J Haematol; 2013 Jun; 161(6):811-20. PubMed ID: 23590807
[TBL] [Abstract][Full Text] [Related]
6. CBL family E3 ubiquitin ligases control JAK2 ubiquitination and stability in hematopoietic stem cells and myeloid malignancies.
Lv K; Jiang J; Donaghy R; Riling CR; Cheng Y; Chandra V; Rozenova K; An W; Mohapatra BC; Goetz BT; Pillai V; Han X; Todd EA; Jeschke GR; Langdon WY; Kumar S; Hexner EO; Band H; Tong W
Genes Dev; 2017 May; 31(10):1007-1023. PubMed ID: 28611190
[TBL] [Abstract][Full Text] [Related]
7. LNK mutations and myeloproliferative disorders.
McMullin MF; Cario H
Am J Hematol; 2016 Feb; 91(2):248-51. PubMed ID: 26660394
[TBL] [Abstract][Full Text] [Related]
8. Selective Interference Targeting of Lnk in Umbilical Cord-Derived Late Endothelial Progenitor Cells Improves Vascular Repair, Following Hind Limb Ischemic Injury, via Regulation of JAK2/STAT3 Signaling.
Lee SH; Lee KB; Lee JH; Kang S; Kim HG; Asahara T; Kwon SM
Stem Cells; 2015 May; 33(5):1490-500. PubMed ID: 25537795
[TBL] [Abstract][Full Text] [Related]
9. Role of the adaptor protein LNK in normal and malignant hematopoiesis.
Gery S; Koeffler HP
Oncogene; 2013 Jun; 32(26):3111-8. PubMed ID: 23045270
[TBL] [Abstract][Full Text] [Related]
10. Lnk adaptor suppresses radiation resistance and radiation-induced B-cell malignancies by inhibiting IL-11 signaling.
Louria-Hayon I; Frelin C; Ruston J; Gish G; Jin J; Kofler MM; Lambert JP; Adissu HA; Milyavsky M; Herrington R; Minden MD; Dick JE; Gingras AC; Iscove NN; Pawson T
Proc Natl Acad Sci U S A; 2013 Dec; 110(51):20599-604. PubMed ID: 24297922
[TBL] [Abstract][Full Text] [Related]
11. Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways.
Tong W; Zhang J; Lodish HF
Blood; 2005 Jun; 105(12):4604-12. PubMed ID: 15705783
[TBL] [Abstract][Full Text] [Related]
12. Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F.
Gery S; Cao Q; Gueller S; Xing H; Tefferi A; Koeffler HP
J Leukoc Biol; 2009 Jun; 85(6):957-65. PubMed ID: 19293402
[TBL] [Abstract][Full Text] [Related]
13. The Polymorphisms in LNK Gene Correlated to the Clinical Type of Myeloproliferative Neoplasms.
Chen Y; Fang F; Hu Y; Liu Q; Bu D; Tan M; Wu L; Zhu P
PLoS One; 2016; 11(4):e0154183. PubMed ID: 27111338
[TBL] [Abstract][Full Text] [Related]
14. Expression of the adaptor protein Lnk in leukemia cells.
Gery S; Gueller S; Nowak V; Sohn J; Hofmann WK; Koeffler HP
Exp Hematol; 2009 May; 37(5):585-592.e2. PubMed ID: 19375649
[TBL] [Abstract][Full Text] [Related]
15. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms.
Oh ST; Simonds EF; Jones C; Hale MB; Goltsev Y; Gibbs KD; Merker JD; Zehnder JL; Nolan GP; Gotlib J
Blood; 2010 Aug; 116(6):988-92. PubMed ID: 20404132
[TBL] [Abstract][Full Text] [Related]
16. The role of LNK/SH2B3 genetic alterations in myeloproliferative neoplasms and other hematological disorders.
Maslah N; Cassinat B; Verger E; Kiladjian JJ; Velazquez L
Leukemia; 2017 Aug; 31(8):1661-1670. PubMed ID: 28484264
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Lnk in mouse induced pluripotent stem cells promotes hematopoietic cell generation.
Tashiro K; Omori M; Kawabata K; Hirata N; Yamaguchi T; Sakurai F; Takaki S; Mizuguchi H
Stem Cells Dev; 2012 Dec; 21(18):3381-90. PubMed ID: 22738147
[TBL] [Abstract][Full Text] [Related]
18. JAK2V617F Megakaryocytes Promote Hematopoietic Stem/Progenitor Cell Expansion in Mice Through Thrombopoietin/MPL Signaling.
Zhang Y; Lin CHS; Kaushansky K; Zhan H
Stem Cells; 2018 Nov; 36(11):1676-1684. PubMed ID: 30005133
[TBL] [Abstract][Full Text] [Related]
19. [Role of LNK gene mutation in pathogenesis of myeloproliferative neoplasms-review].
Chen Y; Wu XQ; Han CS; Zhu P; Wei JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Oct; 21(5):1309-12. PubMed ID: 24156456
[TBL] [Abstract][Full Text] [Related]
20. Lnk adaptor protein down-regulates specific Kit-induced signaling pathways in primary mast cells.
Simon C; Dondi E; Chaix A; de Sepulveda P; Kubiseski TJ; Varin-Blank N; Velazquez L
Blood; 2008 Nov; 112(10):4039-47. PubMed ID: 18753636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
